Guido is the Founder & Chairman of AuroraTT, Board Member at Aurora Science, BoD & SAB Member at Zambon Group, Board Member at Genenta, Board Member at Tethis, SAB Member and Consultant at Italfarmaco and a Board Member at Philogen. He is also a professor and coordinator of the Master in Pharmaceutical Medicine, Milan University and Mario Negri Institute.
From 2012 to 2017, he was Head of Pharma Europe at Novartis, leading Novartis’ General Medicines Business in the European Region, marketing several key products – Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge, in addition to others – and coordinating the Pharma operations. He was overseeing a staff of more than 7,000 employees operating in more than 50 countries, including Russia and Israel. While he was the Head of Pharma Region Europe, Novartis Pharma was the leading pharmaceutical company in Europe.
“What first attracted me to Cellestia is the cutting-edge science, the concrete projects ans the highly experienced team. What made me want to be a part of this journey is the hope their science brings to patients for better, longer lives.”
As Head of Novartis Oncology Europe, Guido led the marketing of different oncology products, including Zometa, Femara, Glivec, Sandostatin and Jakavi. As a member of the Novartis deal committee, Guido played a key role in various partnering operations including Ruxolitinib (Jakavi) from Incyte and Erenumab for the European market from Amgen. He started his career as a Medical Advisor and also had various roles at Sandoz Italia.
Guido has a degree in Medicine from the University of Milan, specializing in Immunology & Allergology and Rheumatology.